PWZ-029

PWZ-029 is a benzodiazepine derivative drug with nootropic effects developed by WiSys,[1] It acts as a subtype-selective, mixed agonist-inverse agonist at the benzodiazepine binding site on the GABA_A receptor, acting as a partial inverse agonist at the α₅ subtype and a weak partial agonist at the α₃ subtype. This gives it a mixed pharmacological profile, producing at low doses memory-enhancing effects but with no convulsant or anxiogenic effects or muscle weakness, although at higher doses it produces some sedative effects.[2]

PWZ-029

Identifiers
IUPAC name 8-chloro-3-(methoxymethyl)-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
PubChem CID	9971547
ChemSpider	8147139^N
ChEMBL	ChEMBL45346^N
Chemical and physical data
Formula	C14H14ClN3O2
Molar mass	291.74 g·mol^−1
3D model (JSmol)	Interactive image
SMILES ClC1=CC=C2C(C(N(CC3=C(COC)N=CN32)C)=O)=C1
InChI InChI=1S/C14H14ClN3O2/c1-17-6-13-11(7-20-2)16-8-18(13)12-4-3-9(15)5-10(12)14(17)19/h3-5,8H,6-7H2,1-2H3^N Key:FXIDXTIMKAEBGY-UHFFFAOYSA-N^N
^NY (what is this?)  (verify)

See also

• GABA_A receptor negative allosteric modulator
• GABA_A receptor § Ligands
• GL-II-73

References

1. US Patent application US2006/258643 A1
2. Savić MM, Clayton T, Furtmüller R, Gavrilović I, Samardzić J, Savić S, Huck S, Sieghart W, Cook JM (May 2008). "PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats". Brain Research. 1208: 150–9. doi:10.1016/j.brainres.2008.02.020. PMC 2577822. PMID 18394590.